Kalli Dircks joined Morgan Stanley in 2006. She is a Managing Director and Co-Head of the Healthcare Equity Capital Markets group. She has been with the firm for 18 years and has held positions across the Equity Syndicate desk and Healthcare Capital Markets.

After earning his Bachelor’s Degree from Menlo College, John received an MS from Stanford University and both a MS and PhD from MD Anderson Cancer Center where he discovered that IL-10 directly activates anti-tumor CD8+ T cells. John conducted post-doctoral work for a year at DNAX Research Institute and became a Scientist at Schering Plough where he developed PEGylated IL-10 (AM0010) as an immunoncology asset. He then founded Targenics, later merged with ARMO Biosciences (briefly a publicly traded company), to clinically develop AM0010 and other immune oncology assets. ARMO Biosciences was acquired by Eli Lilly in 2018 for a $1.6B up front deal. As a founder and Senior Director of Technical Operations at ARMO, John led the manufacturing and pre-clinical research teams.

John served as the Director of Immunoncology R&D at Medimmune LLC and is the author of 28 manuscripts and 52 granted or pending patents. After reviewing the immunoncology space for two years at MedImmune and developing such diverse projects as innate and T cell agonists, CART and other cell therapy projects as well as novel immunostimulatory antibody drug conjugates, John has most recently founded Deka Biosciences. Deka is the next generation cytokine development company created to solve the challenges associated with harnessing the massive potential of cytokine therapy. With the challenges in developing T cell agonists and cell therapy programs, it is likely that cytokine combinations coupled with targeting modalities administered in conjunction with precision patient selection will be clear value drivers for the pharmaceutical industry for years to come.

Dr Selena Daniels, PharmD, PhD, serves as the Deputy Division Director in the Division of Clinical Outcome Assessment at the FDA. She provides direction, oversight and leadership to a team of expert analysts who provide consultation and advice on clinical outcome assessment (COA) endpoint development and validation, including considerations for clinical trial design, conduct, analysis, interpretation and reporting for regulatory determinations of medical product benefit.

Prior to joining the FDA in 2015, Dr Daniels worked in the Health Economic and Outcomes Research (HEOR) group at Allergan, Inc (now Abbvie) for almost five years, where she developed and executed HEOR strategies, as well as developed and implemented innovative COA strategies and endpoints for clinical trials.

Dr Daniels received her Doctor of Philosophy degree in Education at Nova Southeastern University and Doctor of Pharmacy degree at Loma Linda University.

Jennifer Stewart, PhD, has devoted her career to oncology research with an immunology focus. She has worked in both academia and the CRO (contract research organization) space for more than 25 years. Throughout her career she has been involved in both preclinical and clinical research in support of various drug development programs. In her current role at TD2, she is focused on leveraging flow cytometry and predictive biomarkers to drive client programs forward.

Dr. Stewart has a PhD in Biochemistry and Molecular Biology and serves on the Board of the Northwest Flow Cytometry Society providing educational outreach to the local scientific community. She is also co-chair of the AAPS Flow Cytometry Action Programming Committee and is very engaged in biomarker discovery for drug development.

Joana Claverol , is the Clinical Research Director at Barcelona Children’s Hospital Sant Joan de Déu, Spain, where she leads the clinical trials office since 2012 and the Patients engagement in research area since 2015. The Clinical Research Unit is a reference unit for pediatric patients nationally and internationally, specializing in innovative treatments for highly complex patients with rare pediatric diseases. She has more than 13 years of experience in medical and clinical research in the pharmaceutical and biotechnology industry, with special knowledge and experience in drug development and clinical trial design, and all regulatory and methodological aspects related to clinical research. She holds a postgraduate in Senior Management Program of Health Institutions by IESE Business School, a Master in Pharmaceutical Marketing by Universitat Pompeu Fabra, a Master of clinical trials at Universitat de Barcelona and a BS Degree in Biological Sciences by Universitat Autonoma de Barcelona.

A skilled researcher with more than 20 years ‘experience working in the pharmaceutical industry across many different areas. Dr. Dews believes that research should be accessible, understandable, and co-designed and she has a track record of working with patients and organisations to develop shared scientific priorities and outcomes that matter.

Sarah was diagnosed with Young Onset Parkinson’s Disease 5 years ago and finds her purpose inspiring others in the Parkinson’s community to continue to live their best life with a strong hope for a medical breakthrough.

For nearly 30 years she worked in the biopharma industry focused on Prostate Cancer, Lysosomal Storage Disorders (Gaucher Disease, Fabry Disease, MPS 1, Pompe Disease) and with Neuromuscular Specialists treating Spinal Muscular Atrophy.

Since her diagnosis Ms Zenner-Dolan has volunteered as an Ambassador for the Davis Phinney Foundation, a member of the Endpoints Working Group at Critical Path Institute, as a boxing coach at Rock Steady Boxing, and has participated in three clinical research trials.

Dr Patrick Gallogly (he/him), MB BCh BAO (Hons), MSc, MRCP (UK) is a medical advisor for Pfizer UK’s oncology medical affairs team. As part of his non-promotional role, he provides UK medical support throughout a medicine’s life cycle, including liaising with the healthcare community to communicate scientific data and identify areas of unmet medical need as well as supporting with clinical trial site set up. He is a passionate LGBTQ+ advocate, and has taken on diversity, equity, and inclusion roles within Pfizer, as well as partnering with patient organisations to help address healthcare inequalities faced by this community. He obtained his medical degree from Queens University Belfast, and prior to entering the pharmaceutical industry he spent seven years working as an NHS doctor. He is a member of the Royal College of Physicians (UK), and has a master’s degree in clinical and health sciences with ageing from Newcastle University.

Andrew Garvey leads GSK’s global work with patient organizations (excluding the US). He is responsible for leading the work to develop collaborations with patient organizations to bring patient insight into GSK, improve the management of diseases and to strengthen the capabilities of patient organizations. Mr Garvey has worked at GSK for 20 years in sales and marketing, public affairs and communications roles before leading on first GSK’s patient advocacy work in the UK, then across Europe and now globally.

Dr Oleksandr Gorbenko is a global expert in patient science, medical affairs, public health, and community engagement with overall 25 years’ experience in biopharma industry. He graduated as a medical doctor (general practice) in O.Bogomolets’ National Medical University and Shupyk National Healthcare University of Ukraine and later worked on his PhD dissertation in the Ukrainian Institute of Public Health MOH. His experience across pharma includes several medical and commercial roles in affiliates of big biopharma companies (Nycomed/Takeda, Richter Gedeon, GSK) as well as senior global medical roles at GSK and ViiV Healthcare headquarters in the UK. He has an additional experience with UN/UNFPA on community engagement, women empowerment and combating gender-based violence. Since 2019 Dr Gorbenko has a role of Global Patient Affairs Director at Ipsen with the focus on patient experience mapping, developing necessary capacities/capabilities cross-functionally, advice-seeking and insights gathering with patient experts throughout the Medicines Development Continuum, partnership with several patient organisations, substantiation and inclusion of the specific PRO/PCO measurements as endpoints, defining the patient value attributes within the Target Value Profiles (TVP) for new medicines, and other programmes. Board Certified Medical Affairs Professional (ACMA, 2020) and member of MAPS Focus Area Working Group on Patient Centricity.

Emily Hardie is a Senior Clinical Research Associate at Kyowa Kirin International. With 10 years of experience in managing and overseeing clinical operations, she currently leads two real-world evidence studies as part of the Health Economics Outcomes Research (HEOR) team. In her role, Ms Hardie collaborates closely with the project team, contract research organizations (CROs), and investigators to ensure successful study delivery in alignment with study plans and guidelines. She is passionate about leveraging real-world evidence to generate meaningful insights and contributing to evidence-based healthcare decision-making. She is dedicated to advancing patient-centric research and driving innovations for improved patient outcomes. Ms Hardie holds a BSc in Psychology from the University of Leeds.